Graves Disease Market Size, Share and Growth Outlook, 2026

Graves Disease Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Graves Disease Market size is forecast to increase from $5.05 Billion in 2026 to $7.63 Billion in 2034 at a CAGR of 5.3% between 2026 and 2034.

The Graves Disease market report provides detailed analysis and outlook of Graves Disease segments including By Diagnosis Method (Clinical Evaluation, Thyroid Function Tests, Antibody Screening, Imaging Techniques ), By Treatment Modality (Anti-thyroid Medications, Radioactive Iodine Therapy, Surgical, Targeted Immunotherapies & Biologics, Ultrasound-Guided Thermal Ablation), By Phase of Treatment (Initial Diagnosis, Maintenance Therapy), By Patient Age Group (Pediatric, Adult, Geriatric), By End User (Hospitals, Specialty Clinics & Endocrinology Centers, Ambulatory Surgical Centers, Diagnostic Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Graves’ Disease Industry Overview

Advancements in Targeted Therapies Transform Graves’ Disease Management

The Graves’ disease industry is witnessing substantial innovation driven by the development of targeted biologics, antibody-modulating therapies, and novel treatment approaches aimed at improving disease control and reducing complications. Graves’ disease remains one of the most common autoimmune thyroid disorders, frequently associated with hyperthyroidism and thyroid eye disease (TED). Pharmaceutical companies are increasingly focusing on precision therapies that address the underlying autoimmune mechanisms responsible for disease progression, creating new opportunities for improved patient outcomes and personalized treatment strategies.

Thyroid Eye Disease Therapies Expand Treatment Options

A major area of growth within the Graves’ disease market is the treatment of thyroid eye disease. Amgen reported positive Phase 3 results for subcutaneous Tepezza (teprotumumab-trbw) in patients with moderate-to-severe active thyroid eye disease. The study achieved its primary endpoint, demonstrating a 77% proptosis response rate. The availability of a subcutaneous administration option represents a significant advancement compared with traditional intravenous infusion approaches, offering greater convenience for patients and healthcare providers while expanding access to targeted TED treatment.

Antibody-Degrading Platforms Create New Therapeutic Pathways

The industry is increasingly exploring innovative approaches that directly target disease-driving antibodies. Biohaven announced positive clinical biomarker results for its proprietary extracellular degrader technologies, including the MoDE and TRAP platforms. The company plans to initiate pivotal Phase 3 trials for BHV-1300 in Graves’ disease, focusing on the rapid and selective reduction of pathogenic antibodies associated with disease activity. This strategy reflects a growing shift toward precision immunology and targeted autoimmune disease management within the Graves’ disease therapeutics landscape.

Late-Stage Clinical Development Strengthens Market Innovation

Clinical development pipelines continue to expand as new biologic therapies advance toward regulatory review. Viridian Therapeutics reported positive topline findings from its REVEAL-1 Phase 3 clinical trial evaluating elegrobart in patients with active thyroid eye disease. The study successfully met its primary endpoint based on proptosis responder rates, and the company remains on track for a Biologics License Application submission. The advancement of multiple late-stage therapies highlights the increasing emphasis on targeted treatments designed to address both the systemic and ocular manifestations of Graves’ disease.

Graves Disease Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Graves Disease market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Abbott Laboratories, F. Hoffmann-La Roche Ltd., Horizon Therapeutics plc (Amgen), Immunovant, Inc., Pfizer Inc., Novartis AG, Argenx SE, Viridian Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., Teijin Pharma Limited. The Graves Disease market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Graves Disease industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Graves Disease Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Graves Disease companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Graves Disease markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Graves Disease Market Competitive Benchmarking and Company Analysis

Leading companies in Graves Disease industry include- Abbott Laboratories, F. Hoffmann-La Roche Ltd., Horizon Therapeutics plc (Amgen), Immunovant, Inc., Pfizer Inc., Novartis AG, Argenx SE, Viridian Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., Teijin Pharma Limited. The Graves Disease market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Graves Disease Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Graves Disease market remains one of the strongest-performing segments in the country.
The US Graves Disease Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Graves Disease market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Graves Disease industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Graves Disease markets

Canada's strong Graves Disease sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Graves Disease market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Graves Disease Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Graves Disease market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Graves Disease population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Graves Disease industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Graves Disease market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Graves Disease sales through 2034

France Graves Disease companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Graves Disease Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Graves Disease distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Graves Disease Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Graves Disease market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Graves Disease industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Graves Disease industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Graves Disease Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Graves Disease market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Graves Disease market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Graves Disease Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Graves Disease Market Segmentation

By Diagnosis Method
Clinical Evaluation
Thyroid Function Tests
Antibody Screening
Imaging Techniques
By Treatment Modality
Anti-thyroid Medications
Radioactive Iodine Therapy
Surgical
Targeted Immunotherapies & Biologics
Ultrasound-Guided Thermal Ablation
By Phase of Treatment
Initial Diagnosis
Maintenance Therapy
By Patient Age Group
Pediatric
Adult
Geriatric
By End User
Hospitals
Specialty Clinics & Endocrinology Centers
Ambulatory Surgical Centers
Diagnostic Centers

Top Companies in Graves Disease Industry

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Horizon Therapeutics plc (Amgen)
Immunovant, Inc.
Pfizer Inc.
Novartis AG
Argenx SE
Viridian Therapeutics, Inc.
Sun Pharmaceutical Industries Ltd.
Teijin Pharma Limited

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025